Bimodal accurate H2O2 regulation to equalize tumor-associated macrophage repolarization and immunogenic tumor cell death elicitation

Simultaneous implementation of tumor-associated macrophage (TAM) repolarization and immunogenic tumor cell death (ICD) elicitation enables tumor immunotherapy with high efficacy. However, the inconsistency of stimulation tolerance restricts simultaneous implementation. To address this obstacle, we v...

Full description

Saved in:
Bibliographic Details
Published in:Chemical science (Cambridge) 2024-12, Vol.15 (48), p.20403-20412
Main Authors: Zhao, Yan, Kong, Weiheng, Zhu, Jianqing, Qu, Fengli
Format: Article
Language:English
Subjects:
Anticancer properties
Cell death
Chemistry
Damage patterns
Effectiveness
Hydrogen peroxide
Necrosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Simultaneous implementation of tumor-associated macrophage (TAM) repolarization and immunogenic tumor cell death (ICD) elicitation enables tumor immunotherapy with high efficacy. However, the inconsistency of stimulation tolerance restricts simultaneous implementation. To address this obstacle, we validate that an H2O2-mediated regulatory strategy could achieve coordinated occurrences. To accomplish this, a bimodal responsive modulator is constructed, namely ZnO2-ATM (ATM: 3-amino-1,2,4-triazole), as an immune adjuvant to coordinate the occurrence of TAM repolarization and ICD elicitation through the endo/exogenous synergistic responsive production of H2O2. H2O2 produced by ZnO2-ATM reverses the immune-suppressive TAM from an M2 to an M1 phenotype, but induces tumor cell necrosis and promotes damage-related molecular pattern release, thereby evoking ICD. This H2O2-mediation bimodal responsive therapeutic strategy to induce the synergistic occurrence of TAM repolarization and ICD elicitation promotes effective immune effects against tumors, demonstrating that the ZnO2-ATM nanoadjuvant could be expected to provide new tools and paradigms for antitumor immunotherapy.
ISSN:2041-6520
2041-6539
DOI:10.1039/d4sc06305h